In human cancer patients, high tumour-vessel endothelial ADGRL4/ELTD1 expression was shown to correlate with improved overall survival (OS) in patients who subsequently received anti-cancer therapy (head and neck squamous carcinoma, renal, colorectal and ovarian cancers) implicating ADGRL4/ELTD1 as a putative prognostic marker of favourable outcome for these cancers types when treated with systemic therapy. This evidence concerns the gene ADGRL4 and ovarian carcinoma.